Source: Business Wire

Press Release: Genentech : ZappRx Inks Agreement with Leading Global Biopharma Company to Work Together in Idiopathic Pulmonary Fibrosis, Allergic Asthma, and Chronic Idiopathic Urticaria.

BOSTON--(BUSINESS WIRE)--ZappRx announced today that it has entered into an agreement with Genentech. The agreement will start by seeking to improve patient access to specialty drugs in IPF, with an option to continue in allergic asthma, and chronic idiopathic urticaria. ZappRx's goal is to develop an industry-first digital platform for specialty drugs, using a data-driven approach to solving the challenges with today's paper-based, manual, and time-consuming processes currently associated with

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Alexander Hardy's photo - CEO of Genentech

CEO

Alexander Hardy

CEO Approval Rating

70/100

Genentech is a biotechnology company that discovers, develops and commercializes medicines to treat patients with life-t... Read more